It is estimated that the new cancer confirmed cases worldwide would go up to 21.7 million by 2030, according to IARC. This number is sufficient to understand that the market of virus filtration is also going to get a thrust in the near future i.e., 10 to 15 years with an annual growth rate of almost 8% CAGR.
The global virus leak market size in 2021 is estimated to be around US$3 billion. The increasing prevalence of chronic diseases is one of the main factors contributing to growth. The increasing prevalence of chronic diseases such as cancer, diabetes and autoimmune diseases is expected to drive the demand for biologics. According to data from the International Agency for Research on Cancer, there were approximately 14.1 million newly diagnosed cancer cases worldwide in 2012, and this number is expected to reach 21.7 million by 2030, thereby boosting demand. Virus filtering products for R&D and manufacturing applications. Compliance with regulatory frameworks for drug development and production, such as current Good Manufacturing Practice (cGMP) standards, is another important factor that is expected to drive market development.
Major market players:
Merck KGaA; Sartorius; Danaher; Thermo Fisher Scientific; Charles River Laboratory International; General Electric Medical; Asahi Kasei Medical Co., Ltd.; WuXi AppTec; Lonza Group Co., Ltd.; and Clear Cells.
In 2018, due to the increased use of these products in the manufacturing and research of biological products and medical devices, filtration is the market segment that generates the most revenue. In addition, it also provides several advantages, such as not denaturing the protein in the product or sample, and provides high efficiency and purity in laboratory scale and large-scale operations. The filtering part is expected to grow at a profitable rate. During the forecast period, due to the increase in R&D investment of suppliers and the improvement of products. The company invests heavily in research and development to meet the unmet needs of biopharmaceutical, biotechnology and medical device manufacturers. For example, Sartorius invested US$60.4 million in the research and development of innovative products in 2016.
Advances and new product launches help suppliers maintain a dominant market position, which is expected to drive the growth of this segment. For example, in September 2016, Merck KGaA launched a new Viresolve Pro Shield H product for the removal of parvoviruses from therapeutic protein feed streams. This product is used with Viresolve Pro equipment to increase productivity and efficiency. Due to the advancement of products and the increase in R&D and production of biological agents, the chromatography segment is expected to grow at the highest rate. For example, in October 2016, Pall, a Danaher subsidiary, launched the Cadence BioSMB process system, a new type of chromatographic system for the single continuous production of biopharmaceuticals.
Main market regions:
The study on Virus filtration market was global in nature and conducted in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa). In addition, areas like Market size, Y-O-Y growth & Opportunity Analysis, market players competitive study, investment opportunities, demand for future outlook etc. have been covered and displayed in the Global virus filtration market research report to ensure it dives deep to achieve strategic competitive intelligence in the segment.